Biofidelity and CellCarta Partner to Expand Genomic Testing in Global Lung Cancer Clinical Trials
核心洞察
Biofidelity (搜索) and CellCarta (搜索) have formed a strategic partnership to deploy Biofidelity's Aspyre® Lung assay in global clinical trials, enhancing precision medicine solutions.
Aspyre Lung (搜索) simplifies NSCLC (搜索) biomarker detection by analyzing DNA and RNA from tissue and blood samples using a streamlined four-step workflow.
CellCarta (搜索) will validate Aspyre Lung (搜索) in its European and US laboratories, gaining non-exclusive rights for its use in global clinical trials, improving trial enrollment.
Biofidelity (搜索), a genomic solutions company, and CellCarta (搜索), a contract research organization (CRO), have announced a strategic partnership to integrate Biofidelity’s Aspyre® Lung assay into global clinical trials. The collaboration aims to enhance precision medicine by improving the efficiency and reliability of patient enrollment in lung cancer trials.
Aspyre Lung (搜索) simplifies the detection of established non-small cell lung cancer (搜索) (NSCLC (搜索)) biomarkers through a streamlined four-step workflow that analyzes both DNA and RNA from tissue and blood samples. Designed to be compatible with existing qPCR platforms, Aspyre Lung integrates into laboratories globally, aligning with CellCarta (搜索)’s mission to support clinical trials through genomic services.
Partnership Details
Under the agreement, CellCarta (搜索) will validate Aspyre Lung (搜索) in its European laboratories first, followed by its US-based facilities. CellCarta will have non-exclusive rights to utilize Aspyre Lung for clinical trials worldwide. This partnership will provide customers with services leveraging both liquid and tissue biopsy samples, accelerating clinical trial enrollment.
"We are extremely pleased to enter into this strategic partnership with CellCarta (搜索) to expand the use of Aspyre Lung (搜索) to global clinical trials," said Biofidelity (搜索) Co-Founder and CEO Barnaby Balmforth, PhD. "Partnering with CellCarta to make clinical trial enrollment faster and more efficient utilizing Simplified Genomic Profiling (SGP) via Aspyre Lung moves us significantly forward toward fulfilling our mission."
Industry Impact
The collaboration reflects a commitment to advancing genomic solutions in precision medicine. By integrating Aspyre Lung (搜索) into CellCarta (搜索)'s biomarker testing portfolio, the partnership aims to deliver efficient solutions to pharmaceutical and biotech partners.
"We are excited to embark on this partnership with Biofidelity (搜索)," said CellCarta (搜索) CEO Dusty Tenney. "The addition of Aspyre Lung (搜索) to our capabilities marks an advancement in our mission to propel precision medicine with specialized laboratory services."